Company / Accounts Receivable
Cytek Biosciences, Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$62.5M
FY2025
5-year range
$29.8M / $62.5M
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#110 of 138
Health Care
What the data says
Cytek Biosciences, Inc.'s accounts receivable of $63M is lower than 80% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 5 consecutive years, from $17M in FY2020 to $63M in FY2025.
Based on SEC 10-K filings.
$63M in FY2025 with a 5-year CAGR of +29.8%.
Improved from $56M to $63M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +29.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 138This company $62.5M Sector average $1.3B
▼
-95.3% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +29.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 3.2% year-over-year.
- Ranks #110 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.5M | +3.2% |
| FY2024 | $60.6M | +8.3% |
| FY2023 | $55.9M | +14.5% |
| FY2022 | $48.9M | +64.2% |
| FY2021 | $29.8M | +75.2% |
| FY2020 | $17.0M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026